亚洲国产成人久久77-亚洲国产成人久久99精品-亚洲国产成人久久精品hezyo-亚洲国产成人久久精品动漫-人妖hd-人妖ts在线,一本道高清DVD在线视频,2020亚洲永久精品导航,国产久久视频在线视频观看

當(dāng)前位置： 首頁 JCRQ2 期刊介紹(非官網(wǎng))
American Journal Of Cardiovascular Drugs

American Journal Of Cardiovascular DrugsSCIE

國際簡稱：AM J CARDIOVASC DRUG  參考譯名：美國心血管藥物雜志

  • 中科院分區(qū)

    4區(qū)

  • CiteScore分區(qū)

    Q1

  • JCR分區(qū)

    Q2

基本信息：
ISSN：1175-3277
E-ISSN：1179-187X
是否OA：未開放
是否預(yù)警：否
TOP期刊：否
出版信息：
出版地區(qū)：NEW ZEALAND
出版商：Springer International Publishing
出版語言：English
出版周期：Bimonthly
出版年份：2001
研究方向：醫(yī)學(xué)-心血管系統(tǒng)
評(píng)價(jià)信息：
影響因子：2.8
H-index：46
CiteScore指數(shù)：6.7
SJR指數(shù)：0.79
SNIP指數(shù)：0.784
發(fā)文數(shù)據(jù)：
Gold OA文章占比：29.66%
研究類文章占比：51.79%
年發(fā)文量：56
自引率：0.0333...
開源占比：0.2011
出版撤稿占比：0
出版國人文章占比：0.12
OA被引用占比：0.2597...
英文簡介 期刊介紹 CiteScore數(shù)據(jù) 中科院SCI分區(qū) JCR分區(qū) 發(fā)文數(shù)據(jù) 常見問題

英文簡介American Journal Of Cardiovascular Drugs期刊介紹

Promoting rational therapy within the discipline of cardiology, the American Journal of Cardiovascular Drugs covers all aspects of the treatment of cardiovascular disorders, particularly the place in therapy of newer and established agents.

Via a program of reviews and original clinical research articles, the journal addresses major issues relating to treatment of these disorders, including the pharmacology, efficacy and adverse effects of the major classes of drugs; information on newly developed drugs and drug classes; the therapeutic implications of latest research into the aetiology of cardiovascular disorders; and the practical management of specific clinical situations.

The American Journal of Cardiovascular Drugs offers a range of additional enhanced features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by a Key Points summary, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist patients, caregivers and others in understanding important medical advances. The journal also provides the option to include various other types of enhanced features including slide sets, videos and animations. All enhanced features are peer reviewed to the same high standard as the article itself. Peer review is conducted using Editorial Manager?, supported by a database of international experts. This database is shared with other Adis journals.

期刊簡介American Journal Of Cardiovascular Drugs期刊介紹

《American Journal Of Cardiovascular Drugs》自2001出版以來，是一本醫(yī)學(xué)優(yōu)秀雜志。致力于發(fā)表原創(chuàng)科學(xué)研究結(jié)果，并為醫(yī)學(xué)各個(gè)領(lǐng)域的原創(chuàng)研究提供一個(gè)展示平臺(tái)，以促進(jìn)醫(yī)學(xué)領(lǐng)域的的進(jìn)步。該刊鼓勵(lì)先進(jìn)的、清晰的闡述，從廣泛的視角提供當(dāng)前感興趣的研究主題的新見解，或?qū)彶槎嗄陙砟硞€(gè)重要領(lǐng)域的所有重要發(fā)展。該期刊特色在于及時(shí)報(bào)道醫(yī)學(xué)領(lǐng)域的最新進(jìn)展和新發(fā)現(xiàn)新突破等。該刊近一年未被列入預(yù)警期刊名單，目前已被權(quán)威數(shù)據(jù)庫SCIE收錄，得到了廣泛的認(rèn)可。

該期刊投稿重要關(guān)注點(diǎn)：

Cite Score數(shù)據(jù)（2024年最新版）American Journal Of Cardiovascular Drugs Cite Score數(shù)據(jù)

  • CiteScore：6.7
  • SJR：0.79
  • SNIP：0.784
學(xué)科類別 分區(qū) 排名 百分位
大類：Medicine 小類：Cardiology and Cardiovascular Medicine Q1 74 / 387

81%
大類：Medicine 小類：Pharmacology (medical) Q1 63 / 272

77%

CiteScore 是由Elsevier(愛思唯爾)推出的另一種評(píng)價(jià)期刊影響力的文獻(xiàn)計(jì)量指標(biāo)。反映出一家期刊近期發(fā)表論文的年篇均引用次數(shù)。CiteScore以Scopus數(shù)據(jù)庫中收集的引文為基礎(chǔ)，針對(duì)的是前四年發(fā)表的論文的引文。CiteScore的意義在于，它可以為學(xué)術(shù)界提供一種新的、更全面、更客觀地評(píng)價(jià)期刊影響力的方法，而不僅僅是通過影響因子(IF)這一單一指標(biāo)來評(píng)價(jià)。

歷年Cite Score趨勢圖

中科院SCI分區(qū)American Journal Of Cardiovascular Drugs 中科院分區(qū)

中科院 2023年12月升級(jí)版 綜述期刊：否 Top期刊：否
大類學(xué)科 分區(qū) 小類學(xué)科 分區(qū)
醫(yī)學(xué) 4區(qū) CARDIAC & CARDIOVASCULAR SYSTEMS 心臟和心血管系統(tǒng) PHARMACOLOGY & PHARMACY 藥學(xué) 4區(qū) 4區(qū)

中科院分區(qū)表 是以客觀數(shù)據(jù)為基礎(chǔ)，運(yùn)用科學(xué)計(jì)量學(xué)方法對(duì)國際、國內(nèi)學(xué)術(shù)期刊依據(jù)影響力進(jìn)行等級(jí)劃分的期刊評(píng)價(jià)標(biāo)準(zhǔn)。它為我國科研、教育機(jī)構(gòu)的管理人員、科研工作者提供了一份評(píng)價(jià)國際學(xué)術(shù)期刊影響力的參考數(shù)據(jù)，得到了全國各地高校、科研機(jī)構(gòu)的廣泛認(rèn)可。

中科院分區(qū)表 將所有期刊按照一定指標(biāo)劃分為1區(qū)、2區(qū)、3區(qū)、4區(qū)四個(gè)層次，類似于“優(yōu)、良、及格”等。最開始，這個(gè)分區(qū)只是為了方便圖書管理及圖書情報(bào)領(lǐng)域的研究和期刊評(píng)估。之后中科院分區(qū)逐步發(fā)展成為了一種評(píng)價(jià)學(xué)術(shù)期刊質(zhì)量的重要工具。

歷年中科院分區(qū)趨勢圖

JCR分區(qū)American Journal Of Cardiovascular Drugs JCR分區(qū)

2023-2024 年最新版
按JIF指標(biāo)學(xué)科分區(qū) 收錄子集 分區(qū) 排名 百分位
學(xué)科：CARDIAC & CARDIOVASCULAR SYSTEMS SCIE Q2 79 / 220

64.3%
學(xué)科：PHARMACOLOGY & PHARMACY SCIE Q2 158 / 354

55.5%
按JCI指標(biāo)學(xué)科分區(qū) 收錄子集 分區(qū) 排名 百分位
學(xué)科：CARDIAC & CARDIOVASCULAR SYSTEMS SCIE Q2 84 / 220

62.05%
學(xué)科：PHARMACOLOGY & PHARMACY SCIE Q2 163 / 354

54.1%

JCR分區(qū)的優(yōu)勢在于它可以幫助讀者對(duì)學(xué)術(shù)文獻(xiàn)質(zhì)量進(jìn)行評(píng)估。不同學(xué)科的文章引用量可能存在較大的差異，此時(shí)單獨(dú)依靠影響因子(IF)評(píng)價(jià)期刊的質(zhì)量可能是存在一定問題的。因此，JCR將期刊按照學(xué)科門類和影響因子分為不同的分區(qū)，這樣讀者可以根據(jù)自己的研究領(lǐng)域和需求選擇合適的期刊。

歷年影響因子趨勢圖

發(fā)文數(shù)據(jù)

2023-2024 年國家/地區(qū)發(fā)文量統(tǒng)計(jì)
  • 國家/地區(qū)數(shù)量
  • USA89
  • CHINA MAINLAND40
  • Italy21
  • England18
  • France13
  • Spain12
  • Japan11
  • Greece10
  • Australia9
  • Switzerland9

本刊中國學(xué)者近年發(fā)表論文

  • 1、Cost-Effectiveness of Adding Empagliflozin to Standard Treatment for Heart Failure with Preserved Ejection Fraction Patients in China

    Author: Lou, Yake; Hu, Tianyang; Huang, Jing

    Journal: AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS. 2023; Vol. 23, Issue 1, pp. 47-57. DOI: 10.1007/s40256-022-00550-9

  • 2、Antithrombotic Strategy in Secondary Prevention for High-Risk Patients with Previous Acute Coronary Syndrome: Overlap between the PEGASUS Eligibility and the COMPASS Eligibility in a Large Multicenter Registry

    Author: Millesimo, Michele; Elia, Edoardo; Marengo, Giorgio; De Filippo, Ovidio; Raposeiras-Roubin, Sergio; Wanha, Wojciech; Abu-Assi, Emad; Kinnaird, Tim; Ariza-Sole, Albert; Liebetrau, Christoph; Manzano-Fernandez, Sergio; Iannaccone, Mario; Henriques, Jose Paulo Simao; Templin, Christian; Wilton, Stephen B.; Velicki, Lazar; Xanthopoulou, Ioanna; Correia, Luis; Cerrato, Enrico; Rognoni, Andrea; Nunez-Gil, Ivan; Song, Xiantao; Kawaji, Tetsuma; Quadri, Giorgio; Huczek, Zenon; Paz, Rafael Cobas; Juanatey, Jose Ramon Gonzalez; Nie, Shao-Ping; Kawashiri, Masa-Aki; Dominguez-Rodriguez, Alberto; Conrotto, Federico; D'Ascenzo, Fabrizio; De Ferrari, Gaetano Maria

    Journal: AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS. 2023; Vol. 23, Issue 1, pp. 77-87. DOI: 10.1007/s40256-022-00554-5

  • 3、Safety and Tolerability of Tecarfarin (ATI-5923) in Healthy Chinese Volunteers: Multiple Oral Dose-Escalation Phase I Trial

    Author: Zhou, Qiang; Wang, Zhiqiang; Wang, Heming; Chen, Zhidong; Li, Xiaoyi; Dai, Xiangrong; Zhang, Yong; Yu, Xiaohui; Zhou, Renpeng; Hu, Wei

    Journal: AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS. 2023; Vol. 23, Issue 1, pp. 101-112. DOI: 10.1007/s40256-022-00562-5

  • 4、Endothelial-to-Mesenchymal Transition: Potential Target of Doxorubicin-Induced Cardiotoxicity

    Author: Feng, Jie; Wu, Yanqing

    Journal: AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS. 2023; Vol. 23, Issue 3, pp. 231-246. DOI: 10.1007/s40256-023-00573-w

  • 5、Prophylactic Efficacy and Safety of Antithrombotic Regimens in Patients with Stable Atherosclerotic Cardiovascular Disease (S-ASCVD): A Bayesian Network Meta-Regression Analysis

    Author: Zheng, Nan; Zhong, Jinyan; Chen, Xi; Su, Jia; Liu, Chengjiang; Jiang, Longfu

    Journal: AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS. 2023; Vol. 23, Issue 3, pp. 257-267. DOI: 10.1007/s40256-023-00574-9

  • 6、Characteristics and Trends in Clinical Trials of Cardiovascular Drugs in China from 2009 to 2021

    Author: Hao, Jun; Li, Chen; Li, Junrong; Wang, Chuangshi; Li, Yang; He, Chen; Liu, Weida; Li, Sidong; Zuo, Ling; Hui, Wen

    Journal: AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS. 2023; Vol. 23, Issue 3, pp. 301-310. DOI: 10.1007/s40256-023-00575-8

  • 7、Effects of Rosuvastatin and Aspirin on Retinal Vascular Structures in Hypercholesterolemic Patients with Low-to-Moderate Risk of Coronary Artery Disease

    Author: Li Li, Shuang Wang, Huilian Huang, Yi Cai, Yutao Xi, Ying Bai, Changsheng Ma

    Journal: American Journal of Cardiovascular Drugs, 2019, Vol., , DOI:10.1007/s40256-019-00330-y

  • 8、The Efficacy and Safety of Aerosolized Iloprost in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis

    Author: Hongyu Kuang, Qiang Li, Qijian Yi, Tiewei Lu

    Journal: American Journal of Cardiovascular Drugs, 2019, Vol., , DOI:10.1007/s40256-018-00324-2

投稿常見問題

通訊方式：ADIS INT LTD, 41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND, NEW ZEALAND, 1311。